Copyright
copy;2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 28, 2010; 16(36): 4558-4563
Published online Sep 28, 2010. doi: 10.3748/wjg.v16.i36.4558
Published online Sep 28, 2010. doi: 10.3748/wjg.v16.i36.4558
Table 1 Characteristics of patients with crohn's disease and ulcerative colitis n (%)
Phenotypic characteristics | CD CARD15/NOD2 (+) (n = 15) | CD patients CARD15/NOD2 (-) (n = 15) | UC patients (n = 29) |
Male/female | 5 (33.4)/10 (66.7) | 6 (49.1)/9 (50.9) | 15 (51.7)/14 (47.3) |
Median age at diagnosis (range, yr) | 27 (14-48) | 27 (14-48) | |
A1, < 40 | 14 (93.4) | 14 (93.4) | |
A2, ≥ 40 | 1 (6.6) | 1 (6.6) | |
Family history | 4 (26.7) | 3 (21.4) | 1 (3.4) |
Disease behavior | |||
Nonstricturing, nonpenetrating (B1) | 6 (40) | 6 (40) | |
Stricturing (B2) | 3 (20) | 3 (20) | |
Penetrating (B3) | 6 (40) | 6 (40) | |
Perianal disease | 7 (46.6) | 7 (46.6) | |
Disease location | |||
Terminal ileum (L1) | 6 (40) | 6 (40) | |
Colon (L2) | 3 (20) | 3 (20) | |
Ileocolon (L3) | 5 (33.4) | 5 (33.4) | |
Upper gastrointestinal (L4) | 1 (6.6) | 1 (6.6) | |
Pancolitis | 15 (51.7) | ||
Left side | 14 (48.3) | ||
Treatment | |||
Surgery | 6 (40) | 6 (40) | 1 (3.4) |
Infliximab | 8 (53.3) | 6 (40) | 0 (0) |
Immunosuppressants | 7 (46.6) | 7 (46.6) | 10 (34.5) |
No immunosuppressive therapy | 5 (33.4) | 5 (33.4) | 19 (65.5) |
Genotype characteristics | |||
At least one CARD15/NOD2 mutation | 15 (100) | 0 (0) | 4 (13.8) |
ATG16L1 (rs2241880) AA/GA/GG (n) | 0/9/5 | 1/9/4 | 2/11/13 |
IRGM (rs4958847) AA/GA/GG (n) | 0/5/8 | 1/4/9 | 0/7/15 |
IL23R (rs7517847) GG/TG/TT (n) | 2/6/3 | 2/5/7 | 3/10/13 |
-
Citation: Mendoza JL, San-Pedro A, Culebras E, Cíes R, Taxonera C, Lana R, Urcelay E, Torre FL, Picazo JJ, Díaz-Rubio M. High prevalence of viable
Mycobacterium avium subspeciesparatuberculosis in Crohn’s disease. World J Gastroenterol 2010; 16(36): 4558-4563 - URL: https://www.wjgnet.com/1007-9327/full/v16/i36/4558.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i36.4558